Improved overall survival in daily practice of adjuvant chemotherapy in pancreatic cancer patients: Taiwanese single-center study.

e15719Background: Although overall survival (OS) benefit of adjuvant chemotherapy had been demonstrated in the CONKO-001 study, the application of it in daily practice of pancreatic cancer patients did not reach a universal consensus. Methods: Pancreatic cancer patients who had received curative surgery were retrospectively reviewed at National Taiwan University Hospital between January 2001 and December 2013. Neuroendocrine tumors were excluded. Results: Three hundred and nineteen patients were identified (M/F: 193/126; median age of years: 66, range 26-91). Preoperative ECOG performance status (PS) was 0-1 in majority (90.6%) of patients. R0 resection was obtained in 257 (80.6%) patients. The majority of patients (N = 275) had ductal adenocarcinoma (Ad) or adenosquamous carcinoma (As). Adjuvant chemotherapy had been administered in 78 (24.5%) patients, mostly with diagnosis after 2005. The regimens were gemcitabine (N = 28), 5-FU/5-FU analog (N = 36), both (N = 12), or unknown (N = 2). Median OS was 21....